Insider Selling: CeriBell (NASDAQ:CBLL) Major Shareholder Sells 202,368 Shares of Stock

CeriBell, Inc. (NASDAQ:CBLL) major shareholder Tpg Gp A, Llc sold 202,368 shares of the company’s stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $20.12, for a total value of $4,071,644.16. Following the sale, the insider owned 3,765,054 shares in the company, valued at approximately $75,752,886.48. This trade represents a 5.10% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

CeriBell Stock Down 2.6%

CBLL stock traded down $0.51 during mid-day trading on Tuesday, reaching $19.45. The company had a trading volume of 505,081 shares, compared to its average volume of 326,752. The firm has a fifty day simple moving average of $18.90 and a 200 day simple moving average of $19.74. The company has a debt-to-equity ratio of 0.14, a quick ratio of 10.01 and a current ratio of 10.44. The company has a market capitalization of $737.93 million, a price-to-earnings ratio of -11.93 and a beta of 0.85. CeriBell, Inc. has a fifty-two week low of $10.85 and a fifty-two week high of $24.33.

CeriBell (NASDAQ:CBLL) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.13). The company had revenue of $26.49 million for the quarter, compared to analyst estimates of $26.09 million. CeriBell had a negative return on equity of 38.19% and a negative net margin of 63.51%. Analysts forecast that CeriBell, Inc. will post -1.69 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on CBLL shares. Weiss Ratings lowered shares of CeriBell from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, June 12th. Canaccord Genuity Group dropped their target price on CeriBell from $28.00 to $25.00 and set a “buy” rating on the stock in a report on Tuesday, May 12th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, CeriBell has a consensus rating of “Moderate Buy” and an average price target of $22.20.

Hedge Funds Weigh In On CeriBell

Hedge funds have recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. raised its stake in CeriBell by 41.4% during the 4th quarter. Russell Investments Group Ltd. now owns 2,918 shares of the company’s stock worth $64,000 after acquiring an additional 854 shares in the last quarter. Sei Investments Co. grew its holdings in shares of CeriBell by 2.3% during the first quarter. Sei Investments Co. now owns 50,360 shares of the company’s stock worth $923,000 after purchasing an additional 1,125 shares during the last quarter. Caitong International Asset Management Co. Ltd lifted its holdings in shares of CeriBell by 3,971.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock valued at $28,000 after purchasing an additional 1,231 shares during the last quarter. Deutsche Bank AG boosted its position in shares of CeriBell by 1.7% in the 4th quarter. Deutsche Bank AG now owns 85,182 shares of the company’s stock valued at $1,868,000 after purchasing an additional 1,393 shares during the period. Finally, Strs Ohio purchased a new position in CeriBell during the 1st quarter worth approximately $27,000.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.